Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nicholas Likely to Drop Chikungunya Research (India)

This article was originally published in PharmAsia News

Executive Summary

Nicholas Piramal India (NPIL) is expected to withdraw its proposal for a joint venture drug discovery research program with Laboratories Pierre Fabre of France due to the slow regulatory process. The research program was slated to develop the world's first vaccine for chikungunya, which has evolved into an epidemic after spreading throughout southern India and Maharashtra over the last two years. But the Central Drug Control Authority has yet to authorize the project. "We will have to drop the drug research plans for chikungunya, since the Drug Controller General of India (DCGI) is yet to sanction the project," said NPLI Director of Strategic Alliances Swati Piramal. In light of the delays, Piramal explained that there was little else the company could do. "It is almost six months since we applied." The new drugs require the DGCI's approval before they can enter the Indian market. (Click here for more

You may also be interested in...



China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel